Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial

被引：2

作者：

Rosellini, Matteo ^{[1
,2
]}

Tassinari, Elisa ^{[1
,2
]}

Marchetti, Andrea ^{[1
,2
]}

Mollica, Veronica ^{[1
,2
]}

Massari, Francesco ^{[1
,2
,3
]}

机构：

[1] Univ Bologna, Med Oncol Unit, IRCCS Azienda Osped, Bologna, Italy

[2] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[3] Univ Bologna, Med Oncol Dept, IRCCS Azienda Osped, Via Albertoni 15, Bologna, Italy

来源：

EUROPEAN UROLOGY | 2024年 / 85卷 / 01期

关键词：

D O I：

10.1016/j.eururo.2023.09.011

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：97 / 98

页数：2

共 50 条

[41] Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Powles, Thomas
Duran, Ignacio
van der Heijden, Michiel S.
Loriot, Yohann
Vogelzang, Nicholas J.
De Giorgi, Ugo
Oudard, Stephane
Retz, Margitta M.
Castellano, Daniel
Bamias, Aristotelis
Flechon, Aude
Gravis, Gwenaelle
Hussain, Syed
Takano, Toshimi
Leng, Ning
Kadel, Edward E., III
Banchereau, Romain
Hegde, Priti S.
Mariathasan, Sanjeev
Cui, Na
Shen, Xiaodong
Derleth, Christina L.
Green, Marjorie C.
Ravaud, Alain
LANCET, 2018, 391 (10122): : 748 - 757
[42] Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
Cella, David
Gruenwald, Viktor
Nathan, Paul
Doan, Justin
Dastani, Homa
Taylor, Fiona
Bennett, Bryan
DeRosa, Michael
Berry, Scott
Broglio, Kristine
Berghorn, Elmer
Motzer, Robert J.
LANCET ONCOLOGY, 2016, 17 (07): : 994 - 1003
[43] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
Hutson, Thomas E.
Lesovoy, Vladimir
Al-Shukri, Salman
Stus, Viktor P.
Lipatov, Oleg N.
Bair, Angel H.
Rosbrook, Brad
Chen, Connie
Kim, Sinil
Vogelzang, Nicholas J.
LANCET ONCOLOGY, 2013, 14 (13): : 1287 - 1294
[44] A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC)
Dizman, Nazli
Adra, Nabil
Vaishampayan, Ulka N.
Xiao, Lianchun
Yuan, Ying
Campbell, Matthew T.
Gao, Jianjun
Zurita, Amado J.
Jonasch, Eric
Tannir, Nizar M.
Shah, Amishi Yogesh
Msaouel, Pavlos
Hahn, Andrew Warren
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
Choueiri, Toni K.
Merchan, Jaime R.
Figlin, Robert
Mcdermott, David F.
Arrowsmith, Edward
Michaelson, M. Dror
Tykodi, Scott S.
Heath, Elisabeth, I
Spigel, David R.
D'Souza, Anishka
Kassalow, Laurent
Perini, Rodolfo F.
Vickery, Donna
Bauer, Todd M.
LANCET ONCOLOGY, 2025, 26 (01): : 64 - 73
[46] Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, Louis
Spira, Alexander
Ballinger, Marcus
Kowanetz, Marcin
Vansteenkiste, Johan
Mazieres, Julien
Park, Keunchil
Smith, David
Artal-Cortes, Angel
Lewanski, Conrad
Braiteh, Fadi
Waterkamp, Daniel
He, Pei
Zou, Wei
Chen, Daniel S.
Yi, Jing
Sandler, Alan
Rittmeyer, Achim
LANCET, 2016, 387 (10030): : 1837 - 1846
[47] Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
Le Cesne, Axel
Ray-Coquard, Isabelle
Bui, Binh Nguyen
Adenis, Antoine
Rios, Maria
Bertucci, Francois
Duffaud, Florence
Chevreau, Christine
Cupissol, Didier
Cioffi, Angela
Emile, Jean-Francois
Chabaud, Sylvie
Perol, David
Blay, Jean-Yves
LANCET ONCOLOGY, 2010, 11 (10): : 942 - 949
[48] CaboPoint, a phase II, open-label study of cabozantinib as second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC), whose disease progressed after therapy with checkpoint inhibitors (CPIs)
Albiges, Laurence
Schmidinger, Manuela
Pioger, Naila Taguieva
Perol, David
Gruenwald, Viktor
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[49] Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Dummer, Reinhard
Ascierto, Paolo A.
Gogas, Helen J.
Arance, Ana
Mandala, Mario
Liszkay, Gabriella
Garbe, Claus
Schadendorf, Dirk
Krajsova, Ivana
Gutzmer, Ralf
Chiarion-Sileni, Vanna
Dutriaux, Caroline
de Groot, Jan Willem B.
Yamazaki, Naoya
Loquai, Carmen
Moutouh-de Parseval, Laure A.
Pickard, Michael D.
Sandor, Victor
Robert, Caroline
Flaherty, Keith T.
LANCET ONCOLOGY, 2018, 19 (05): : 603 - 615
[50] Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3TiNivo-2 Study
Choueiri, Toni K.
Albiges, Laurence
Barthelemy, Philippe
Iacovelli, Roberto
Emambux, Sheik
Molina-Cerrillo, Javier
Garmezy, Benjamin
Barata, Pedro
Basu, Arnab
Bourlon, Maria
Moon, Helen
Ratta, Raffaele
McKay, Rana R.
Chehrazi-Raffle, Alexander
Hammers, Hans
Heng, Daniel Y. C.
Braendle, Edgar
Beckermann, Kathryn E.
McGregor, Bradley A.
Motzer, Robert J.
LANCET, 2024, 404 (10460):

← 1 2 3 4 5 →